Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
May 28, 2026
CIBC (CM) Q2 2026 Earnings Preview: What Analysts Expect on May 28

CIBC (CM) Q2 2026 Earnings Preview: What Analysts Expect on May 28

Key Takeaways

  • CIBC is scheduled to report second quarter 2026 results on May 28, 2026, before market open.
  • Analyst consensus points to diluted earnings per share of approximately $1.78.
  • Revenue expectations center on modest year-over-year growth amid stable Canadian banking conditions.
  • Investors will focus on net interest margin trends, credit quality metrics, and capital ratios.
  • Guidance updates on expenses and loan growth are expected to shape the outlook.
  • Historical stock reactions to CIBC earnings have varied based on beats or misses versus consensus.

Earnings Context and Why It Matters

Canadian Imperial Bank of Commerce, commonly known as CIBC, operates across personal and business banking, wealth management, and capital markets. Its fiscal second quarter ends April 30, making this report a timely update on performance through the first half of the calendar year. Recent quarters have shown resilience in net interest income despite rate environment shifts, and this release offers fresh insight into deposit competition, mortgage demand, and commercial lending trends in Canada. For investors, the results help gauge the bank’s ability to sustain profitability and return capital amid evolving economic signals.

Earnings Expectations

Consensus estimates compiled by financial data providers call for diluted earnings per share of roughly $1.78 for the quarter ended April 30, 2026. Revenue is projected to show modest year-over-year gains, supported by stable net interest margins. Analysts will also monitor provisions for credit losses and efficiency ratios. In the prior quarter ended January 31, 2026, CIBC reported adjusted diluted EPS of $2.76, exceeding expectations at the time. Stocks in the Canadian banking sector have historically shown measured moves around earnings, with reactions driven by deviations from consensus and any updates to full-year guidance. I also checked this using Tickeron’s AI Screener to see how CM compares to peers on key fundamentals.

Market Reaction and Investor Sentiment

Heading into the release, sentiment toward CIBC shares reflects cautious optimism tied to Canada’s steady economic backdrop and expectations for steady dividend growth. Key risk factors include potential pressure on margins from deposit competition and any surprises in commercial real estate exposure. Pre-earnings trading has remained range-bound, with investors awaiting confirmation of resilient credit metrics and capital generation that could support future buybacks or dividend increases. One thing that stands out is how these factors have influenced CM historically around reporting dates.

Forward Outlook and Key Factors to Monitor

Following the earnings release, attention will turn to management commentary on expense management and digital banking investments. Loan growth across residential mortgages and commercial segments remains a focal point, as does the trajectory of the net interest margin in a potentially stable rate environment.

Credit quality indicators, including the ratio of non-performing loans and provisions for credit losses, will provide clues about consumer and business health. Capital ratios such as the Common Equity Tier 1 (CET1) ratio will also be scrutinized for any signals on capital return plans.

Broader industry dynamics, including regulatory updates from the Office of the Superintendent of Financial Institutions and competitive pressures in wealth management, could influence the longer-term outlook. Investors should watch for any revisions to full-year targets on revenue and efficiency.

How Tickeron’s AI Tools Fit Into My Research Process

When preparing for reports like this one, I often turn to Tickeron’s AI Screener to quickly filter Canadian banks and compare technical setups alongside the fundamental metrics that matter most for earnings season. It helps surface relevant peers and patterns without spending hours on manual reviews. The platform’s customizable options for industry, performance, and signals make it a practical addition to the standard analyst workflow I follow. AI Screener

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: CM

Contributor

Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.


CM in downward trend: 10-day moving average broke below 50-day moving average on August 31, 2026

The 10-day moving average for CM crossed bearishly below the 50-day moving average on August 31, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 9 of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 75%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 17, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CM as a result. In 26 of 69 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 38%.

The Moving Average Convergence Divergence Histogram (MACD) for CM turned negative on September 23, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 25 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 58%.

CM moved below its 50-day moving average on September 04, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 52%.

The Aroon Indicator for CM entered a downward trend on October 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 25 of 48 cases where CM's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 52%.

Following a +2.18% 3-day Advance, the price is estimated to grow further. Considering data from situations where CM advanced for three days, in 211 of 375 cases, the price rose further within the following month. The odds of a continued upward trend are 56%.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is 4 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 25 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 21, placing this stock worse than average.

The Tickeron PE Growth Rating for this company is 29 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 45 (best 1 - 100 worst), indicating steady price growth. CM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of 80 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: CM's P/B Ratio (2.437) is slightly higher than the industry average of (1.866). P/E Ratio (15.236) is within average values for comparable stocks, (14.888). Projected Growth (PEG Ratio) (1.713) is also within normal values, averaging (2.139). Dividend Yield (0.028) settles around the average of (0.026) among similar stocks. P/S Ratio (4.527) is also within normal values, averaging (3.867).

Notable companies

The most notable companies in this group are JPMorgan Chase & Co (NYSE:JPM), Bank of America Corp (NYSE:BAC), HSBC Holdings PLC (NYSE:HSBC), Wells Fargo & Co (NYSE:WFC), Citigroup (NYSE:C), Barclays PLC (NYSE:BCS).

Industry description

Major banks are among the biggest companies in the world, often times with global reach and market capitalizations in the multi-billions. Large banks often have multiple arms spanning different disciplines, from deposits, to investment banking, to wealth management and insurance. The biggest banks often have key competitive advantages over smaller players in the industry in terms of brand recognition, cost of capital, and efficiency. Think J.P. Morgan, Bank of America, Wells Fargo, and Citigroup.

Market Cap

The average market capitalization across the Major Banks Industry is 206.84B. The market cap for tickers in the group ranges from 1.04M to 894.72B. JPM holds the highest valuation in this group at 894.72B. The lowest valued company is BACRP at 1.04M.

High and low price notable news

The average weekly price growth across all stocks in the Major Banks Industry was -2%. For the same Industry, the average monthly price growth was -8%, and the average quarterly price growth was 14%. FRBT experienced the highest price growth at 3%, while BBVA experienced the biggest fall at -6%.

Volume

The average weekly volume growth across all stocks in the Major Banks Industry was 17%. For the same stocks of the Industry, the average monthly volume growth was 49% and the average quarterly volume growth was -22%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 68
P/E Growth Rating: 33
Price Growth Rating: 48
SMR Rating: 4
Profit Risk Rating: 21
Seasonality Score: 52 (-100 ... +100)
View a ticker or compare two or three
CM
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a major bank

Industry MajorBanks

Industry
Investment Trusts Or Mutual Funds
Address
81 Bay Street
Phone
+1 416 980-3096
Employees
49824
Web
https://www.cibc.com
Interact to see
Advertisement
UBXG stock surged +79% over the last 30 days, driven by heightened trading volume and positive market sentiment amid broader technology sector trends. Over the past quarter, the stock rose +61%, reflecting recovery from earlier lows near its 52-week bottom.
CVGI stock surged approximately +89% over the last 30 days, driven by strong Q4 2025 earnings beat on revenue and positive 2026 guidance. Over the past quarter, shares rose about +126%, reflecting improved profitability, debt reduction, and a key partnership announcement.
SAFX stock surged +104% over the past 30 days, driven by positive updates on a $10 million capital raise and merger progress. Over the past quarter, the stock rose +44%, reflecting recovery from lows amid renewable energy sector interest and strategic developments.
LONA stock surged +80% over the past 30 days, driven by positive analyst upgrades, executive appointments, and full-year financial updates highlighting pipeline progress. Over the past quarter, shares rose +48%, reflecting improved investor sentiment in biotech amid clinical advancements.
Lifetime Brands (LCUT) stock surged +77% over the last 30 days, driven by a strong Q4 earnings beat and a Zacks Rank #1 (Strong Buy) upgrade that reflects an improved earnings outlook. Over the past quarter, shares rose +48%, supported by profitability gains despite softer sales, with adjusted EBITDA reaching $50.8 million for full-year 2025.
CURV stock surged approximately +73% over the last 30 days, driven primarily by a positive reaction to Q4 and fiscal 2025 earnings that beat expectations on EPS and revenue. Over the past quarter, the stock is up around +55%, reflecting recovery from lows near $1 amid ongoing store optimization and sub-brand launches
Blaize Holdings, Inc. (BZAI) focuses on artificial intelligence (AI)-enabled edge computing solutions, offering programmable AI processors and platforms for verticals such as smart cities, defense, retail, and enterprise markets. The company's core revolves around hardware like the Graph Streaming Processor (GSP) AI accelerator, compute cards, and software tools including Blaize AI Studio—a no-code/low-code environment for deploying AI models without source code expertise. Based in El Dorado Hills, California, and founded in 2010, it went public through a merger in early 2025.
Comstock Holding Companies, Inc. (CHCI) operates as an asset manager, developer, and operator of mixed-use and transit-oriented properties, mainly in the greater Washington, D.C. metropolitan area. The company targets high-growth urban and suburban markets, overseeing a portfolio that spans residential, commercial, hospitality, and parking assets near key metro stations. Its asset-light, fee-based model delivers recurring revenue through property management, leasing, development services, and asset recapitalization for institutional investors, family offices, and governments.
ARM stock surged +26% over the past 30 days, driven by announcements of in-house chip production and strong analyst upgrades amid AI enthusiasm. Over the past quarter, the stock climbed +38%, reflecting robust Q3 earnings beat with 26% revenue growth and data center royalty doubling.
Sable Offshore Corp. (SOC) is an independent oil and gas company focused on offshore operations in federal waters off California. The company owns and operates three platforms in the Santa Ynez Unit (SYU), spanning 16 federal leases across approximately 76,000 acres, along with subsea pipelines for crude oil, natural gas, and produced water transport to onshore facilities. Its core business model centers on restarting and developing prolific fields like the SYU, which had been idle due to regulatory and legal hurdles following a 2015 pipeline spill.
When geopolitical turmoil sends markets into chaos, most retail traders freeze — but Tickeron's Energy (OXY, EOG, DVN, FANG, APA, MTDR) AI Trading Agent is built to thrive in exactly these conditions. This 15-minute and 60-minute AI-powered robot has delivered a +76.22% annualized return with a 64.21% win rate and a Profit Factor of 2.70 — trading six of the most volatile and opportunity-rich energy tickers on the market.
The global energy sector is on fire — literally and figuratively. With crude oil prices swinging 20–30% in response to geopolitical flashpoints, OPEC+ production cuts, and escalating conflicts in Eastern Europe and the Middle East, traders who aren't using AI-powered tools are flying blind. Enter Tickeron's Energy (Oil & Gas – E&P) AI Trading Agent — a 60-minute signal robot built exclusively around five high-impact Exploration & Production tickers, now posting a staggering +49% Annualized Return and +1,251% 30-Day Annualized Return, with $14,703 in closed-trade P&L on a $30,000 simulated balance.
From what I see, Cheniere Energy Partners (CQP) holds a commanding position through its ownership and operation of the Sabine Pass LNG terminal in Louisiana, the largest LNG production facility in the U.S. with approximately 30 million tonnes per annum (mtpa) capacity across six trains, alongside the connected Creole Trail Pipeline. This setup makes CQP a leader in U.S. LNG exports, which have accounted for about 11% of global supply in recent years. The company's ~80% contracted production through long-term sale and purchase agreements (SPAs) provides revenue stability, with weighted average remaining lives of around 13 years.
In my view, Regeneron Pharmaceuticals holds a strong leadership position in biotechnology, thanks to its proprietary VelociSuite technologies, including VelocImmune for fully human antibody discovery. This enables a robust pipeline across immunology, oncology, ophthalmology, and rare diseases. The company's integrated model—from discovery to commercialization—drives high R&D productivity, with approximately 45 clinical programs and key partnerships like Sanofi for Dupixent and Bayer for EYLEA.
As I review argenx SE's place in the market, its strong footing in immunology stands out. This commercial-stage biopharmaceutical company focuses on differentiated antibody therapies for severe autoimmune diseases. The flagship product, VYVGART (efgartigimod), a first-in-class neonatal Fc receptor (FcRn) inhibitor, has secured leadership in generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP), with approvals across the U.S., Europe, and Japan. The Immunology Innovation Program (IIP) fuels a robust pipeline, featuring next-generation FcRn candidates like ARGX-213 and ARGX-124, alongside first-in-class assets such as empasiprubart (C2 inhibitor, ARGX-117) and adimanebart (MuSK agonist).
I've long admired Alnylam Pharmaceuticals as the pioneer in RNA interference (RNAi) therapeutics, a gene-silencing technology that has delivered six approved products, including AMVUTTRA (vutrisiran), ONPATTRO (patisiran), GIVLAARI (givosiran), and OXLUMO (lumasiran). The company's proprietary platform, enhanced by GalNAc conjugation for liver targeting and emerging extra-hepatic delivery innovations, creates a solid competitive moat in precision genetic medicines.
As I review BeOne Medicines AG's position in the oncology space, what stands out is its role as a global leader with a diversified portfolio that includes both commercial-stage therapies and a deep pipeline targeting hematologic and solid tumors. The flagship product, BRUKINSA (zanubrutinib), a Bruton's Tyrosine Kinase (BTK) inhibitor, has secured approvals in over 75 markets, solidifying its dominance in chronic lymphocytic leukemia (CLL) and other blood cancers. This is complemented by TEVIMBRA (tislelizumab), an anti-PD-1 antibody approved in more than 50 markets for various indications, which broadens its reach in immunotherapy.
Rio Tinto holds a premier position as one of the world's largest mining companies, anchored by low-cost, Tier 1 assets. Its Pilbara iron ore operations in Australia deliver industry-leading margins, thanks to integrated rail and port infrastructure that gives it a structural cost advantage over higher-cost producers. In copper, the company has significant stakes in Escondida, the world's largest copper mine, and full ownership of Oyu Tolgoi in Mongolia, setting it up well to benefit from tightening supply as demand surges for electrification and renewables.
I've always been impressed by how Visa (V) commands the global payments landscape. As an open-loop network, it connects issuers, acquirers, merchants, and consumers without issuing cards or extending credit itself. The VisaNet platform processes over 65,000 transactions per second across more than 200 countries, supporting a ~52% share of the global credit card market and ~60% of debit. This scale generates powerful network effects, where greater adoption benefits everyone involved and creates formidable barriers to entry.
Following the Kenvue consumer health spin-off, Johnson & Johnson has transformed into a focused healthcare leader, emphasizing Innovative Medicine (pharmaceuticals) and MedTech (devices). In my view, this repositioning sharpens the company's edge in high-margin areas such as oncology, immunology, neuroscience, cardiovascular, surgery, and vision, where its diversified portfolio and R&D efficiency provide clear competitive advantages.
CIBC (CM) Q2 2026 Earnings Preview: What Analysts Expect on May 28